保留射血分数的心力衰竭患者螺内酯起始注册随机介入试验（SPIRRIT-HFpEF）：原理与设计

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure Pub Date : 2024-09-16 DOI:10.1002/ejhf.3453

Lars H. Lund, Stefan James, Adam D. DeVore, Kevin J. Anstrom, Marat Fudim, Keith D. Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L. Fleg, Song Yang, Michael Fu, Camilla Hage, Claes Held, Patric Karlström, Magnus Nygren, Eric D. Peterson, Tymon Pol, Shelly Sapp, Johan Sundström, Ollie Östlund, Jonas Oldgren, Bertram Pitt

{"title":"保留射血分数的心力衰竭患者螺内酯起始注册随机介入试验（SPIRRIT-HFpEF）：原理与设计","authors":"Lars H. Lund, Stefan James, Adam D. DeVore, Kevin J. Anstrom, Marat Fudim, Keith D. Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L. Fleg, Song Yang, Michael Fu, Camilla Hage, Claes Held, Patric Karlström, Magnus Nygren, Eric D. Peterson, Tymon Pol, Shelly Sapp, Johan Sundström, Ollie Östlund, Jonas Oldgren, Bertram Pitt","doi":"10.1002/ejhf.3453","DOIUrl":null,"url":null,"abstract":"Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"2 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design\",\"authors\":\"Lars H. Lund, Stefan James, Adam D. DeVore, Kevin J. Anstrom, Marat Fudim, Keith D. Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L. Fleg, Song Yang, Michael Fu, Camilla Hage, Claes Held, Patric Karlström, Magnus Nygren, Eric D. Peterson, Tymon Pol, Shelly Sapp, Johan Sundström, Ollie Östlund, Jonas Oldgren, Bertram Pitt\",\"doi\":\"10.1002/ejhf.3453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3453\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3453","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

矿物皮质激素受体拮抗剂（MRAs）对射血分数保留和轻度降低的心力衰竭（HFpEF/HFmrEF）的疗效尚未确定。传统的随机对照试验既复杂又昂贵。保留射血分数的心力衰竭患者螺内酯起始注册随机介入试验（SPIRRIT-HFpEF）是一项独特、务实的基于注册的随机对照试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

查看原文本刊更多论文

The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Heart Failure 医学-心血管系统

CiteScore

27.30

自引率

11.50%

发文量

365

审稿时长

1 months

期刊介绍： European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.